Eric I. Richman - 17 Mar 2021 Form 3/A - Amendment Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Executive Officer, Director
Signature
/s/ Trevor Bossi, Attorney-in-Fact
Issuer symbol
GANX
Transactions as of
17 Mar 2021
Net transactions value
$0
Form type
3/A - Amendment
Filing time
21 Apr 2022, 16:47:52 UTC
Date Of Original Report
17 Mar 2021
Next filing
21 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GANX Stock Option (right to buy) 17 Mar 2021 Common Stock 26,424 $3.38 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was inadvertently omitted from the original Form 3 filed on March 17, 2021.
F2 One-third of the shares underlying this option vested on December 15, 2021, and the remaining shares vested or will vest in 24 equal monthly installments thereafter, subject to the Reporting Person providing service the the Issuer.

Remarks:

On the original Form 3 filed on March 17, 2021, the Reporting Person's relationship the the Issuer omitted listing him as a Director.